Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting

NACompletedINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

December 28, 2018

Primary Completion Date

August 5, 2019

Study Completion Date

September 12, 2019

Conditions
HemostasisBleeding
Interventions
DEVICE

HemoStyp

During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.

DEVICE

Surgicel

During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.

Trial Locations (1)

91505

Raymond Schaerf, Burbank

All Listed Sponsors
lead

United Health Products, Inc.

INDUSTRY

NCT03654560 - Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting | Biotech Hunter | Biotech Hunter